ResearchBib Share Your Research, Maximize Your Social Impacts
Sign for Notice Everyday Sign up >> Login


Journal: Journal of the Grodno State Medical University (Vol.54, No. 2)

Publication Date:

Authors : ; ; ;

Page : 120-122

Keywords : acute leukemia; cytogenetic abnormalities; tyrosine kinase inhibitor; target therapy;

Source : Downloadexternal Find it from : Google Scholarexternal


Patients with mixed-phenotype acute leukemia (MPAL) are characterized by resistance, which may be associated with a high proportion of patients with adverse cytogenetic abnormalities. To date, there have been no large prospective controlled trials of treatment of MPAL. According to the few reports treatment regimen elaborated for acute lymphoblastic leukemia, followed by allogenic stem cell transplantation can be recommended; patients with translocation (9; 22) are recommended to add a tyrosine kinase inhibitor. Still unknown remains the role of immunophenotypic and genetic markers when choosing a post-remission chemotherapy and treatment strategies, as well as the use of target therapy for Ph-negative MPAL. This article presents the clinical cases of diagnosis and treatment of patients with MPAL.

Last modified: 2016-08-18 22:13:19